Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors
Clinical trial NCT01311713 · TERMINATED
Trial details
- NCT number
- NCT01311713
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-05-02
- Primary completion
- 2013-10-16
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.